Depressing. Can’t wait for the bubble to pop and employment to start the recovery process.
I also feel incredibly bad for those pursuing college/university education at this time, there’s a lot of uncertainty.
Pleased to share our native glycomics workflow preserving O-acetylation, detecting this labile modification in rat (53%) and mouse (9%) serum N-glycans.
Integrally, O-acetyls are invisible under standard reductive conditions.
Now published at Molecular Omics.
Link: academic.oup.com/molecular-om...
News in Proteomics Research blog post | JASMS pulled together an amazing piece on the passing of Amina Woods proteomicsnews.blogs...
---
#proteomics #prot-other
I haven't heard anything about those specific areas, sorry.
I think the Eclipse/Ascend have the capability. I don't know what the new tribrid will be able to achieve that the existing tribrids can't, beyond some reconfiguring to reduce noise at the high m/z range for DMT.
Those still scare me but that phosphoryl group has me hopeful we’d see it, despite your research showing positive mode is best for it.
Awesome news! Gabe’s MS research for carbohydrate analysis is always insightful. #glycotime
Vanquish Neo users, has anyone had a crack at a third party substitute for this needle? #Proteomics #TeamMassSpec
Well that explains a lot about me.
(Sugars ionise best in negative mode)
Nice, looking forward to the publication.
I’m mostly looking at released glycans/oligosaccharides so Helios gets us in the door to then do our molecule class-specific searching and triggering.
It is unfortunate that we can’t share code without permission, but it’s fun to show what is possible.
Link to Helios for those interested (I’m sure you’re already familiar with it)
pubmed.ncbi.nlm.nih.gov/40939636/
I’m a big fan of Helios and Nova (Thanks @dschweppe.bsky.social lab).
Our glyco-specific software uses those libraries because they’re so well documented, and then we extend upon them with the glyco context.
I’m more than happy to donate 95% of my wealth if everyone helps me become a billionaire 😀
I think my favourite was tryptophan
Ah, I see you work for OpenAI!
I've been using Thermo's IAPI for real-time MS control since July last year. Some are worried that real-time interventions can cause crashes.
For the first time since using the IAPI, the instrument had an error but surprisingly, this was just an Easy-IC.
I can't recommend IAPI enough, it's great.
The high capacity rf carpet is a direct quote from one of the patents, it’s cheating a bit.
It doesn’t do terribly at this prompt which might be seen as a shower thought:
“Field X has technique Y, how would we change technique Y to address problems in field Z?”
I think they’re fancy search engines
Oh no, Gemini re-invented the FTICR.
Glycomics data repository size (GlycoPOST) has started to accelerate beyond the linear trend.
It's a good time to take some interest in the field, particularly for anything multi-omics.
#glycotime
That's the beauty of trade secrets and knowledge that just isn't published for other various reasons. No LLM is going to be able to get that info to use it.
"desfucosylated derivatives revealed that affinities of three of the four peptides rely on the fucose moiety. Striking losses in binding affinity were observed compared to their fucosylated counterparts, thus validating the glycan reprogramming approach."
Shows how important sugars are!
"Ribosomal Translation and Display Selection of Cyclic Glycopeptides through Genetic Reprogramming"
It's limited to incorporation of glycosyl-amino acids to the N-terminus of peptides, but this work is a leap, generating a wide range of potential applications
#glycotime
pubs.acs.org/doi/10.1021/...
I guess too much of a good thing (scan speed) can be a bad thing! Excited to see what becomes of this acquisition.
RTS on an Astral with Chimerys for 2026 is maybe a bit too lofty of a goal but I want to put it out there.
It doesn't even mention ion mobility, which is an "obvious" solution to the bottlenecks that are described in your papers.
I feel like a Masters student (1-2 years MS experience) would be able to identify better avenues for improvement than an LLM.
Those connections are so tenuous, they're statistically unlikely to be an output from an LLM.
Most at risk are academics because the future directions of their papers are used as content, so the obvious next steps are output.
Here's what I get when I search you, it's all incremental improvements:
Acquisition news for bottom up and top down proteomics with Thermo acquiring Proteinaceous and MSAID.
Proteinaceous was founded in 2016 (possibly earlier) as a spin out from Neil Kelleher’s lab at Northwestern.
MSAID was spun out from Mathias Wilhelm and Bernhardt Kuster’s labs in 2019.
True, but I find discussions really only happen here. LinkedIn is too shallow.
I was a little worried about Twitter being so high up, but it’s a 2023 survey so I think we can safely assume it’s all Bluesky now.
